breast cancer news from FierceBioResearcher
NewsNanoparticles carry drugs into cells; new gene signature for metastasis; cancer researchers call for new funds
Nanotechnology Researchers at MIT have been designing new nanoparticles that can be used to transport therapeutics through the cell membrane barrier. Read more...
ALSO NOTED: Maryland hands out $23M for stem cell research;New study highlights genetic link to diabetes; Lawmakers want $200M
Stem Cell Research Maryland has handed out $23 million for stem cell research, with the lion's share of the funds going to Johns Hopkins and the University of Maryland. Read more...
Two therapeutic targets identified for metastasis
Scientists at Memorial Sloan-Kettering Cancer Center in New York City have identified the molecular process by which breast cancer cells spread to other tissue during metastasis. A signaling Read more...
ALSO NOTED: New candidate to replace hESCs; Genetic tests proliferate; new research building planned;
Stem Cell Research Medistem Laboratories says they've found a new adult stem cell in menstrual blood that may prove an effective replacement for human embryonic stem cells. Read more...
Heart hormones used to cure cancer in mice
Researchers have revealed that the heart is much more than a blood pump. The organ produces hormones that the body requires to lower blood pressure and flush water and salt out of the body. And now Read more...
ALSO NOTED: Gates Foundation backs orphan drug program; Yamanaka forecasts looming stem cell cures; RNA blocks cancer; Autism l
Spotlight The Gates Foundation has put up $19 million to fund a hunt for a new drug to treat sleeping sickness, a malady that affects huge numbers of the world's poorest people but rarely attracts Read more...
ALSO NOTED: Disgraced scientist applies for research funds; Cats genetically altered to glow in the dark;
Stem Cell Research Hwang Woo-suk, the disgraced South Korean scientist, wants to get back into stem cell research. He's a member of a research team that has applied for government funds to back new Read more...
Synthetic compound works as targeted cancer therapy
A synthetic compound developed in the lab at UT Southwestern Medical Center mimics the cellular protein Smac, broadcasting a message to cancer cells that triggers their destruction. In a study Read more...
ALSO NOTED: Stem cells produce insulin; Breakthrough in breast cancer genomics;Stem Cell Research Using stem cells extracted from umbilical cords, researchers at the University of Texas Medical Branch teamed with scientists in the UK were able to coax them to produce insulin, offering an approach to curing diabetes. Dr. Randall Urban, who led the study, said that they were on the first rung of the ladder. The news follows a report from last week that Geron had used embryonic stem cells to create new … Read more...Hot nanoprobes used to slow tumor growth in animalsA research team at UC Davis has used hot nanoprobes to slow the development of aggressive breast cancer in mice and now plans to begin human studies of the new approach. Working with Triton BioSystems, the researchers combined magnetized iron-oxide nanospheres with radiolabeled monoclonal antibodies and then hid them inside polymers and sugars to protect them from the animals' immune system. Injected into the bloodstream, these microscopic nanoprobes attached to receptors on the surface … Read more... | Press ReleasesPRESS RELEASE: FDA Approves IXEMPRA, a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer FDA Approves IXEMPRA, a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer PRINCETON, N.J., Oct. 16 -- Bristol-Myers Squibb Company announced today that the U.S. Read more... PRESS RELEASE: Hollis-Eden Pharmaceuticals Presents HE3235 Update at ASCO Breast Cancer Symposium Hollis-Eden Pharmaceuticals Presents HE3235 Update at ASCO Breast Cancer Symposium Preclinical Data Show Lasting Anti-Tumor Effect of Novel Drug Candidate SAN DIEGO -- Hollis-Eden Pharmaceuticals, Read more... PRESS RELEASE: Genentech Announces Resubmission of sBLA for Avastin in Combination with Paclitaxel Genentech Announces Resubmission of Supplemental Biologics License Application for Avastin in Combination with Paclitaxel for First-Line Metastatic Breast Cancer Genentech announced Read more... |
Get more breast cancer coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends

